Insulet Corporation
Insulet Announces Third Quarter 2025 Financial Results and Raises Full Year Guidance
Summary
On November 6, 2025, Insulet Corporation announced its financial results for the third quarter of 2025, reporting a 29.9% increase in revenue to $706.3 million. The company also raised its full-year revenue and margin guidance, citing strong Omnipod sales and strategic partnerships. Insulet's gross margin expanded by 290 basis points to 72.2%, and the company's net income rose to $87.6 million. The exhibit includes detailed financial statements and reconciliations of GAAP to non-GAAP measures.
Profitelligence Alerts
Get alerts for PODD
Be first to know when Insulet Corporation files with the SEC.
Filing Categories
Advertisement
About Insulet Corporation
Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.
Official SEC Documents
Advertisement